Trials / Completed
CompletedNCT00527033
A Study of YM178 in Patients With Symptomatic Overactive Bladder
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study in Patients With Symptomatic Overactive Bladder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 842 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Examine which dose of YM178 is the best in terms of efficacy, safety and tolerability compared to placebo
Detailed description
To investigate the dose-response relationship of YM178 in terms of efficacy, safety and tolerability, and also the superiority of YM178 over placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YM178 | Oral |
| DRUG | Placebo | Oral |
Timeline
- Start date
- 2007-09-11
- Primary completion
- 2008-04-03
- Completion
- 2008-04-03
- First posted
- 2007-09-10
- Last updated
- 2024-10-31
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00527033. Inclusion in this directory is not an endorsement.